Singapore markets closed
Straits Times Index
3,410.81 -29.07 (-0.85%) Nikkei
40,912.37 -1.28 (-0.00%) Hang Seng
17,799.61 -228.67 (-1.27%) FTSE 100
8,203.93 -37.33 (-0.45%) Bitcoin USD
56,912.58 +1,421.98 (+2.56%) CMC Crypto 200
1,180.68 -28.01 (-2.32%)
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SS)
Shanghai - Shanghai Delayed price. Currency in CNY
Add to watchlist
At close: 03:00PM CST
| Previous close | 21.71 |
| Open | 21.70 |
| Bid | 22.31 x 0 |
| Ask | 22.32 x 0 |
| Day's range | 21.65 - 22.40 |
| 52-week range | 20.38 - 32.08 |
| Volume | |
| Avg. volume | 8,636,623 |
| Market cap | 54.322B |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | 29.76 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.42 (1.93%) |
| Ex-dividend date | 09 Aug 2023 |
| 1y target est | N/A |
- Investing.com
Cevira Phase III trial for non-surgical HSIL treatment meets primary endpoint
Photocure ASA (OSE: PHO) and its partner Asieris Pharmaceuticals (SSE (LON:SSE): 688176) announced on Wednesday that their multinational Phase III clinical trial for Cevira (APL-1702) has successfully met its primary endpoint. Cevira, a photodynamic drug-device combination product, is in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL).
© 2024 Yahoo. All rights reserved.